Perforating pilomatricoma: transepithelial elimination or not.
We present a 56-year-old woman with a perforating pilomatricoma in the left eyebrow region. Histologically, the tumor consisted mainly of basophilic cells and shadow cells, and the tumor components were being eliminated through an ulcer with damage to the epithelial structures. In past reports of perforating pilomatricoma, this elimination pattern has often been described as transepithelial elimination. In many patients with perforating pilomatricoma, elimination is accompanied by ulceration and epithelial damage. Mehregan recently stated that elimination accompanied by epidermal necrosis and superficial ulceration constituted one form of transepithelial elimination. Epidermal necrosis and ulceration generally constitute severe damage. However, when Mehregan first proposed the concept of transepithelial elimination, it was defined as a phenomenon with relatively little or no damage to the epithelial structures, differentiating it from other types of elimination. This original definition makes transepithelial elimination a unique and interesting phenomenon, and its most important feature is that there is relatively little or no damage to the epithelial structures. Therefore, the terms "epidermal necrosis" and "ulceration" should not be used in association with transepithelial elimination. Hence, in patients with perforating pilomatricoma, the elimination of tumor components from ulcers with damage to the epithelial structures, as seen in the present case, should not be described as transepithelial elimination.
Honda
Yoshihide
Y
Department of Dermatology, Tokyo Medical University, Japan.
Oh-i
Tsunao
T
Koga
Michiyuki
M
Tokuda
Yasumoto
Y
D001707:Biopsy, Needle; D003475:Curettage / Q000379:methods; D004598:Electrosurgery; D004848:Epithelium / Q000473:pathology / Q000601:surgery; D005138:Eyebrows; D005260:Female; D006201:Hair Diseases / Q000473:pathology* / Q000601:surgery*; D006801:Humans; D008875:Middle Aged; D018296:Pilomatrixoma / Q000473:pathology* / Q000601:surgery*; D011379:Prognosis; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000473:pathology* / Q000601:surgery*; D016896:Treatment Outcome